TCMD

Tactile Systems

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 1

Sell signal 1

Revenue Beats Expectation

EPS Below Expectations

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About TCMD

Tactile Systems Technology, Inc.

A leader in developing at-home therapies for underserved chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease

Industry

Healthcare Equipment and Supplies

Established Date

01/30/1995

Listing Date

07/28/2016

Exchange

NASDAQ Stock Exchange

Full-time Employees

1037

Fiscal Year Ends

12-31

Website

www.tactilemedical.com

Security Type

Common stock

Office address

3701 Wayzata Blvd, Suite 300, Minneapolis, Minnesota 55416

Business

Introduction

Tactile Systems Technology, Inc., was established on January 30, 1995. The company is a medical technology company that develops and sells home physiotherapy devices for the treatment of chronic diseases. They focus on improving the standard of physiotherapy for the treatment of chronic diseases, improving the effectiveness of treatment and quality of life, and helping to control the reduction of health care expenditure. They have a unique and developable platform to provide home therapy programs across the United States. This medical method has been recognized by the government and taxpayers as the key to controlling the rising medical costs in the continuous development. Their initial focus area of treatment is vascular disease, with the aim of raising the standard of home physiotherapy for lymphedema and chronic venous insufficiency. Their main products are two kinds, one is Flexitouch System, which is used for home treatment of lymphedema, and the other is ACTitouch System, which provides physiotherapy equipment worn all day for patients with chronic venous insufficiency.

Company Financials

EPS

TCMD has released its 2024 Q4 earnings. EPS was reported at 0.40, versus the expected 0.28, beating expectations. The chart below visualizes how TCMD has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

TCMD has released its 2024 Q4 earnings report, with revenue of 85.59M, reflecting a YoY change of 10.22%, and net profit of 9.72M, showing a YoY change of 18.46%. The Sankey diagram below clearly presents TCMD’s revenue sources and cost distribution.